|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400087302 |
|
最近更新日期: Date of Last Refreshed on: |
2024-07-24 16:55:23 |
|
注册时间: Date of Registration: |
2024-07-24 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
术后运动干预对结直肠肿瘤患者影响的多中心、前瞻性、开放性、随机对照研究 |
|
Public title: |
A multicenter,prospective, open, randomized, controlled study on the impact of postoperative exercise intervention on patients with colorectal cancer |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
术后运动干预对结直肠肿瘤患者影响的多中心、前瞻性、开放性、随机对照研究 |
|
Scientific title: |
A multicenter,prospective, open, randomized, controlled study on the impact of postoperative exercise intervention on patients with colorectal cancer |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
吴茜 |
研究负责人: |
吴茜 |
|
Applicant: |
Wu Qian |
Study leader: |
Wu Qian |
|
申请注册联系人电话: Applicant telephone: |
+86 139 1621 9036 |
研究负责人电话:
Study leader's |
+86 139 1621 9036 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
qian_wu2010@163.com |
研究负责人电子邮件: Study leader's E-mail: |
qian_wu2010@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市静安区延长路301号上海市第十人民医院护理部 |
研究负责人通讯地址: |
上海市静安区延长路301号上海市第十人民医院护理部 |
|
Applicant address: |
Nursing Depatment, 301 Yanchang Road, Jing'an District, Shanghai |
Study leader's address: |
Nursing Depatment, 301 Yanchang Road, Jing'an District, Shanghai |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
上海市第十人民医院 |
||
|
Applicant's institution: |
Shanghai Tenth People's Hospital |
||
|
研究负责人所在单位: |
上海市第十人民医院 |
||
|
Affiliation of the Leader: |
Shanghai Tenth People's Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
SHSY-IEC-5.0/23K60/P01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
上海市第十人民医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Shanghai Tenth People's Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-07-14 00:00:00 | ||
|
伦理委员会联系人: |
曲伸;孙冉冉 |
||
|
Contact Name of the ethic committee: |
Qun Shen;Sun Ranran |
||
|
伦理委员会联系地址: |
上海市静安区延长路301号 |
||
|
Contact Address of the ethic committee: |
301 Yanchang Road, Jing'an District, Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 6630 1604 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
上海市第十人民医院护理部 |
||||||||||||||||||||||
|
Primary sponsor: |
Nursing Department,Shanghai Tenth People's Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市静安区延长路301号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
301 Yanchang Road, Jing'an District, Shanghai |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
上海市第十人民医院 |
||||||||||||||||||||||
|
Source(s) of funding: |
Shanghai Tenth People's Hospital |
||||||||||||||||||||||
|
研究疾病: |
结直肠肿瘤 |
||||||||||||||||||||||
|
Target disease: |
Colorectal neoplasms |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
1、评估运动干预对结直肠癌化疗患者生活质量的影响 2、运动干预方案依从性及该方案对结直肠癌化疗患者身体功能、营养、心理健康的干预效果及生存时间以及对化疗不良反应的影响,从而全面评估运动干预方案对患者身心健康及预后的作用 |
||||||||||||||||||||||
|
Objectives of Study: |
1.Assessment of exercise intervention on the quality of life of patients with colorectal cancer chemotherapy 2.exercise adherence and assessment of effects of physical function, nutrition,mental health to colorectal patients undergoing chemotherapy |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.年龄>18 岁; 2.依据美国癌症协会指南中病理学或影像学诊断标准确诊为结直肠癌 II-IV期的患者; 3.正在接受抗肿瘤化学治疗且通过运动安全评估可以进行运动锻炼的患者; 4.主要器官功能正常,即符合下列标准: (1)ECOG体能状态评分为0~1或者KPS分数>70; (2)血常规检查标准符合:HB≥90g/L (14天内未输血),ANC≥ 1.5×10^9/L,PLT≥80×10^9/L,Alb≥2.8g/dL,serum lipase and amylase<1.5×ULN(正常值上限); (3)生化检查需符合以下标准:TBIL≤1.5×ULN(正常值上限);ALT和AST≤2.5×ULN;如有肝转移,则ALT和AST≤5×ULN;血清Cr≤1×ULN,内生肌酐清除率>50 ml/min; (4)心脏射血分数>55%; (5)血清中钙、钾、镁的水平在标准范围内 5.没有出血性疾病或凝血功能障碍; 6.具备正常的精神状态与社会参与能力、感知觉与参与能力; 7.自愿签署书面知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
1.age>18; 2.According to the American cancer society guidelines in pathology or imaging diagnostic criteria for patients diagnosed with colorectal cancer II - IV; 3.Undergoing anticancer chemotherapy and pass the safety assessment of exercise; 4.Normal function of major organs,That meet the following criteria: (1)the original ECOG physical status score of 0 ~ 1 or KPS score > 70 "dictionary" (2)HB≥90g/L (14),ANC≥ 1.5×10^9/L,PLT≥80×10^9/L,Alb≥2.8g/dL,serum lipase and amylase<1.5×ULN (3)TBIL≤1.5×ULN();ALTAST≤2.5×ULN;,ALTAST≤5×ULN;Cr≤1×ULN,The endogenous creatinine clearance>50 ml/min; (4)EF>55%; (5)The levels of serum calcium, potassium, magnesium, within the scope of the standard 5.No hemorrhagic disease or blood coagulation dysfunction; 6.Normal state of mind and social participation ability, sense of awareness and participation ability; 7.Written informed consent signed voluntarily. |
||||||||||||||||||||||
|
排除标准: |
1.既往有其他恶性肿瘤病史 2.研究开始前 4 周内参加过其他药物临床试验 3.身体活动障碍无法完成规定运动方案者 4.研究者判断依预计生存时间<3 个月 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.A history of other malignant tumors 2.patients involved other drugs in clinical trials four weeks prior to the start of the study 3.patients have physical activity barriers and cannot complete required movement scheme 4.the survival time of patients <3 months |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-07-01 00:00:00至 To 2026-06-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2023-11-03 00:00:00 至 To 2026-06-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
采用平衡随机方法对受试者进行分组 以EXCEL随机函数(RAND)生成约110个随机数(大约入组样本总数100的110%),均乘以2后再以EXCEL简单取整函数(INT)取整,得0或1的随机数各约55个。参试患者顺序取随机数,为1者入试验组,为0者入对照组。入组完成90%时(即某组入组约45个时)进行关于年龄的平衡检验。而后按平衡检验结果决定其后入组者选择入组,以消除年龄指标失衡为原则。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Use a balanced random approach to group subjects Use EXCEL random function (RAND) to generate about 110 random numbers (approximately 110% of the total number of samples in the group), All again after 2 times in order to EXCEL simple integral function (INT) integer,Have to 0 or 1 random number about 55.Volunteers patients take random number sequence,1 into the experimental group , 0 into a control.Into the set is 90% complete (that is, the group set is about 45) about the balance of age inspection.Then decide according to the balance inspection result into the group of people in this group, to eliminate the imbalance age indicators for the principle. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
开放 |
|
Blinding: |
Open-label |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
1、本研究后期将在临床试验公共管理平台(ResMan Research Manager);www.medresman.org.cn上共享研究数据,目前研究仍处于前期招募阶段,共享数据将在于2026年12月陆续上传至网站。公开内容包括原始数据和研究计划书2、采用临床试验公共管理平台想公众共享研究数据,共享数据包括元数据和病例记录表的记录数据。3、数据的保存和管理均采用规范化的病例记录表和基于互联网的EDC系统。4、研究中招募的所有患者的知情同意书在隐去患者真实姓名后加入共享原始数据的内容。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
1.Later in this study, the research data will be shared on the clinical trial public management platform (ResMan Research Manager); www.medresman.org.cn.At present, the research is still in the early recruitment stage, and the shared data will be uploaded to the website in December 2026. The public content includes raw data and research proposals.2. The clinical trial public management platform is used to share the research data with the public, including metadata and case record table.3.The data were saved and managed by standardized case record table and Internet-based EDC system.4.The main results are as follows: 1. The informed consent forms of all patients recruited in the study were added to share the original data after hiding the patients' real names. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
本研究数据包采用病例数据记录表的形式进行数据采集和管理 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
This research data packets in the form of case data form for data collection and management |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |